SKBI [SKYSTAR BIO-PHARMACEUTICAL] 10-Q: (Original Filing)

[SKYSTAR BIO-PHARMACEUTICALMPANY FORM10-Q INDEX Page Number PART I.FINANCIAL INFORMATION Item 1. Financial Statements (unaudited) 1nsolidated Balance Sheets of September 30, 2009 and December 31, 2008 1nsolidated Statements of Operations and Othermprehensiveome (Loss) for the Three Months and Nine Months Ended September 30, 2009 and 2008] [CERTIFICATION I, Weibing Lu, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, Bennet P. Tchaikovsky, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Weibing Lu Chief Executive Officer v166458_ex32-1.htm 5 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Bennet P. Tchaikovsky Chief Financial Officer (Principal Financial and Accounting Officer) v166458_ex32-2.htm 6 EX-32.2]

By | 2016-02-05T04:52:40+00:00 November 16th, 2009|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: (Original Filing)

[Skystar Bio-Pharmaceuticalmpany Announces Third Quarter 2009 Financial Resultsmpany Reports Record Quarterly Revenue of $12.78 Million andjusted Netome of $4.25 Million; andjusted EPS of $0.61 Per Share XI'AN, CHINA November 16, 2009ystar Bio-Pharmaceuticalmpany (NASDAQ:BI) THIRD QUARTER 2009 HIGHLIGHTS Revenuereased 27.1% period over period to $12.78 million.]

By | 2016-02-05T04:54:28+00:00 November 16th, 2009|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: Skystar Bio-Pharmaceuticalmpany Announces Third Quarter 2009 Financial Resultsmpany

[Skystar Bio-Pharmaceuticalmpany Announces Third Quarter 2009 Financial Resultsmpany Reports Record Quarterly Revenue of $12.78 Million andjusted Netome of $4.25 Million; andjusted EPS of $0.61 Per Share XI'AN, CHINA November 16, 2009ystar Bio-Pharmaceuticalmpany (NASDAQ:BI) THIRD QUARTER 2009 HIGHLIGHTS Revenuereased 27.1% period over period to $12.78 million.]

By | 2016-02-05T04:55:22+00:00 November 16th, 2009|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results -- Q3 2009 revenue increased 106.3% to $15.6 million; Q3 Gross Margins of 77.0% -- Q3 2009 net income increased 459.2% to $3.1 million with EPS of $0.13 -- Revenue for the first nine months increased 52.5 % to $36.2 million; net income increased 112.9% to $8.8 million with EPS]

By | 2016-03-03T15:25:35+00:00 November 13th, 2009|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009

[Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results -- Q3 2009 revenue increased 106.3% to $15.6 million; Q3 Gross Margins of 77.0% -- Q3 2009 net income increased 459.2% to $3.1 million with EPS of $0.13 -- Revenue for the first nine months increased 52.5 % to $36.2 million; net income increased 112.9% to $8.8 million with EPS]

By | 2016-03-03T15:27:18+00:00 November 13th, 2009|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] SC 13D: (Original Filing)

[1 Name of Reporting Person Andrew Barron Worden I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds PF Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Number of 7 Sole Voting Power Shares Owned]

By | 2016-03-03T15:28:42+00:00 November 13th, 2009|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] SC 13D: 1 Name of Reporting Person Andrew Barron Worden

[1 Name of Reporting Person Andrew Barron Worden I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds PF Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Number of 7 Sole Voting Power Shares Owned]

By | 2016-03-03T15:30:15+00:00 November 13th, 2009|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[Biostar Pharmaceuticals, Announces Record Third Quarter 2009 Financial Results -- Q3 2009 revenuereased 106.3% to $15.6 million; Q3 Gross Margins of 77.0% -- Q3 2009 netomereased 459.2% to $3.1 million with EPS of $0.13 -- Revenue for the first nine monthsreased 52.5 % to $36.2 million; netomereased 112.9% to $8.8 million with EPS of $0.37]

By | 2016-02-07T17:58:17+00:00 November 13th, 2009|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar